Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study...

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study of two Phase III trials that compared its Lymphoseek radiopharmaceutical injection with a commonly used agent. Lymphoseek "demonstrated reliable detection of lymph nodes" in patients with breast cancer and melanoma over a period of 15 minutes up to 30 hours, a time range that may be encountered in a clinic. (PR)